When ICANS and CRS occur concurrently tocilizumab should be used with caution as it can lead to deterioration of ICANS (Figure 2).22 The cornerstones of treatment of HLH are corticosteroids and an IL-6R antagonist. Here, IL6R is linked to congenital rubella syndrome.